Jason Hoffman, PharmD, RPh

Jason Hoffman, PharmD, RPhis a medical writer specializing in the field of oncology and is based in Boston. Jason contributes news articles, creates drug showcases, develops case studies, and maintains the treatment regimen charts on Cancer Therapy Advisor. After studying pharmacy at Northeastern University and working as a pharmacy intern at Dana-Farber Cancer Institute, Jason transitioned to medical communications to have a greater impact on a wider audience. His interests include hiking, playing tennis, and traveling.

Most Recent Articles by Jason Hoffman, PharmD, RPh

Identifying Treatment Failure in Patients With Chronic Myeloid Leukemia

Identifying Treatment Failure in Patients With Chronic Myeloid Leukemia

By

One study's results may be especially relevant for patients eligible for treatment discontinuation.

Can Vismodegib Induce Melanoma in Patients Treated for Basal Cell Carcinoma?

Can Vismodegib Induce Melanoma in Patients Treated for Basal Cell Carcinoma?

By

Two cases raise the question of whether abnormal activation of the hedgehog signaling pathway can lead to a protective effect on melanomas.

Could Switching to Interferon Avoid an Abnormal Ovarian Response in CML?

Could Switching to Interferon Avoid an Abnormal Ovarian Response in CML?

By

Among female patients with CML, fertility preservation with ovarian stimulation can be challenging if patients require continuation of TKIs until HSCT.

Myeloma: Proteasome Inhibitors and IMiDs May Increase Risk of Cardiovascular Complications

Myeloma: Proteasome Inhibitors and IMiDs May Increase Risk of Cardiovascular Complications

By

Patients with underlying cardiovascular disease and/or baseline hypertension and coronary artery disease may be at a higher risk.

NSCLC: Liquid Biopsy May Predict Patient Response to Immune Checkpoint Inhibition

NSCLC: Liquid Biopsy May Predict Patient Response to Immune Checkpoint Inhibition

By

Liquid biopsy can be useful in cases where small bronchial biopsies contain a low number of tumor cells, and the repeatability of liquid biopsies can offer new approaches for monitoring patients treated with immunotherapy.

More Articles by Jason Hoffman, PharmD, RPh

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs